Brian Hilberdink promoted to President of Novo Nordisk Canada

He has been with the Denmark-headquartered insulin specialist for 20 years

Novo Nordisk has welcomed Brian Hilberdink as President, Novo Nordisk Canada Inc.

Hilberdink is an accomplished executive with 20 years of global and domestic experience developing and executing Novo Nordisk's commercial strategy.

He was previously Vice President, Diabetes Marketing and Market Access, Novo Nordisk Canada. Prior to this, he was Corporate Vice President, Global Marketing, Novo Nordisk A/S, and led the commercialisation of the company's future insulin portfolio, from Phase II clinical development until the first launches in Europe and Japan.

Hilberdink also has experience working in the US where, as Director, Brand Management, he led multiple brand teams during a period of significant growth for Novo Nordisk US.

You may also like

Manufacturing

Novo Nordisk acquires license to Ascendis Pharma's TransCon tech for up to $286m

Novo Nordisk will use the technology to develop, manufacture and commercialise therapeutics for metabolic and cardiovascular diseases
Regulatory

Novo Nordisk's haemophilia A/B drug Alhemo gets positive opinion from the EMA

The subcutaneous, self-administering prophylactic can allow a patient to produce thrombin, a clotting agent, even in the presence of inhibitors
Regulatory

Novo Nordisk's Wegovy gains positive opinion from the EMA for cardiovascular event risk reduction

The GLP-1 medication has proven effective at reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease
Manufacturing

Novo Nordisk teams up with Bio Farma and Indonesian government to enhance national diabetes drug accessibility

The collaboration will aim to enhance the availability of insulin and other diabetes drug products in Indonesia, where diabetes is one of the top three killers annually
Distribution

Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride

The two companies aim to expand the distribution of benzalkonium chloride within Europe
Regulatory

Anti-IL-21 monoclonal antibody licensed by Almirall

NN-8828, the IL-21 blocker, is exclusively owned by Almirall and will be used to treat immune inflammatory dermatological diseases
Manufacturing

BioInnovation adds eight early-stage companies to acceleration programme

Lomo, Novozymes and Amalus are all among the eight countries selected by BII to join its acceleration programme for early-stage companies looking to strike out into the pharmaceutical industry
Subscribe now